The Problem

Early-stage diabetes research is underfunded, and patients are disconnected from research teams and projects

Diabetes is a chronic disease affecting hundreds of millions worldwide, yet funding for research and innovation remains highly centralized, slow-moving, and often limited for early-stage projects. Traditional funding models rely heavily on large institutions, limiting innovation and delaying the development of new treatments and products. At the same time, people living with diabetes, who can bring significant benefit to research projects, are often disconnected from research teams and projects. Collectively, these factors delay breakthroughs and cures.